Although ulcer patients didn’t make out so well under the standard treatment, the medical community did just fine. Millions of patients required the constant service of gastroenterologists and surgeons, while pharmaceutical companies got rich: the antacids Tagamet and Zantac were the first true blockbuster drugs, taking in more than $1 billion a year.
